Jeenah Moon/Getty Images News
Madrigal Pharmaceuticals (MDGL) announced on Friday an exclusive global license agreement with Pfizer (PFE) for ervogastat, an experimental therapy that could enhance the clinical effects of Rezdiffra, MDGL’s FDA-approved treatment for a liver disease called metabolic dysfunction-associated steatohepatitis.
Per the